Determining the Value Contribution of Selexipag for the Treatment of Pulmonary Arterial Hypertension (PAH) in Spain Using Reflective Multi-Criteria Decision Analysis (MCDA)

Orphanet Journal of Rare Diseases - United Kingdom
doi 10.1186/s13023-018-0966-4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC


Related search